Watch for final FDA approval of LIBERVANT in January 2027 (ages 12+) and the PDUFA date of March 29, 2027 for label expansion to ages 6-11. Milestone payments and royalty revenue will begin upon commercial launch, expected April 2027.
Price Chart
Executive Summary
Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal film for seizure clusters, receiving a $10.0M upfront fee and up to $47.5M in milestones plus mid-teens royalties. Aquestive will also serve as exclusive manufacturer under a 20-year supply agreement. Commercial launch is anticipated in April 2027, subject to final FDA approval.
Key Financial Metrics
Key Facts
- Aquestive received $10.0M upfront from Eton for exclusive U.S. commercialization rights to LIBERVANT.
- Aquestive is eligible for up to $47.5M in regulatory and commercial milestone payments.
- Aquestive will receive mid-teens percentage royalties on annual net sales of LIBERVANT.
- Aquestive entered a 20-year exclusive supply agreement to manufacture LIBERVANT for Eton.
- LIBERVANT has tentative FDA approval for ages 2-5 and 12+; full approval expected after VALTOCO orphan exclusivity expires Jan 10, 2027.
- Commercial launch anticipated in April 2027, subject to final FDA approval.
- U.S. seizure rescue market exceeds $450 million annually per the press release.
- Patient survey showed 71% preferred buccal film over nasal spray (13%) assuming equal efficacy.
Financial Impact
$10.0M upfront + up to $47.5M milestones + mid-teens royalties on U.S. net sales
Risk Factors
- Final FDA approval is contingent on expiration of VALTOCO orphan exclusivity on Jan 10, 2027.
- Label expansion to ages 6-11 has a PDUFA date of March 29, 2027 and may not be approved.
- Commercial success depends on Eton's execution; Aquestive has no control over sales.
- Milestone payments are contingent on regulatory and commercial achievements.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001398733-26-000056 |
| Document: etonaquestivelibervantpr.htm | 0001398733-26-000056 |
| Document: 0001398733-26-000056-index-headers.html | 0001398733-26-000056 |
| Document: 0001398733-26-000056-index.html | 0001398733-26-000056 |
| Document: 0001398733-26-000056.txt | 0001398733-26-000056 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 8-K | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $3.97 (−2.22%) |
Oct 15, 2026 11d ago | Press Release | $4.06 $4.13 | ▲ +1.72% | ▲ +2.74% | $3.97 (−2.22%) |
Oct 14, 2026 12d ago | 8-K | $4.61 $4.08 | ▼ −11.50% | ▼ −11.95% | $3.97 (−13.88%) |
Oct 7, 2026 19d ago | SC 13G | $4.62 $4.61 | ▼ −0.22% | ▲ +0.76% | $3.97 (−14.07%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.62 $4.61 | ▲ +0.22% | ▼ −0.76% | $3.97 (+14.07%) |
Sep 29, 2026 27d ago | 8-K | $4.67 $4.61 | ▼ −1.28% | ▼ −3.23% | $3.97 (−14.99%) |
Sep 25, 2026 4w ago | 8-K | $4.68 $4.55 | ▼ −2.78% | ▼ −2.56% | $3.97 (−15.17%) |
Sep 17, 2026 5w ago | 8-K | $4.66 $4.82 | ▲ +3.43% | ▲ +2.83% | $3.97 (−14.81%) |
Sep 16, 2026 5w ago | Insider Cluster | $4.82 $4.70 | ▼ −2.49% | ▼ −5.05% | $3.97 (−17.63%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.29 $4.80 | ▲ +11.89% | ▲ +13.08% | $3.97 (−7.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers